drugset
drugset / Trial / NCT00370539

Combined PDT and Intravitreal Bevacizumab vs Combination of PDT, Intravitreal Bevacizumab and Triamcinolone for Neovascular AMD

NCT00370539 ↗

Phase 3 Unknown Shahid Beheshti University of Medical Sciences
RandomizedParallel-groupSingle-blindTreatment

Summary

To compare the efficacy and safety of photodynamic therapy (PDT) combined with intravitreal bevacizumab versus combination of photodynamic therapy , intravitreal bevacizumab and intravitreal triamcinolone for neovascular AMD.

Timeline

Start
2006-09
Primary completion
—
Completion
2006-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Triamcinolone Acetonide Other / unclassified — Intravitreal
Background Bevacizumab Monoclonal antibody — Intravitreal
Background Verteporfin Other / unclassified — —

Indications

wet macular degeneration